Anjie H. Zhu
Key Laboratory Of Carcinogenesis And Translational Research
Beijing, China
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Real-World Study on the Efficacy and Safety of Incadronate Disodium in Treating Bone Metastases of Advanced Breast Cancer.
Journal: Current pharmaceutical design
Published: September 17, 2025
Comparison of case-based learning and traditional teaching methods in advanced breast cancer education for oncology residents in the standardized training.
Journal: Biochemistry and molecular biology education : a bimonthly publication of the International Union of Biochemistry and Molecular Biology
Published: July 12, 2024
HER2 status results in an unstable switch from primary to recurrent breast cancer.
Journal: Neoplasma
Published: February 29, 2024
Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2- metastatic breast cancer: A single center real-world study in China.
Journal: Cancer medicine
Published: September 04, 2023
Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world setting.
Journal: Frontiers in oncology
Published: October 21, 2022
Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA.
Journal: Cancer biology & medicine
Published: May 26, 2021
A Phase II, Single-Arm Study of Apatinib and Oral Etoposide in Heavily Pre-Treated Metastatic Breast Cancer.
Journal: Frontiers in oncology
Published: October 19, 2020
The metabolism of blood glucose and lipid in breast cancer patients after the first chemotherapy
Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology]
Published: August 27, 2020
Steroidal aromatase inhibitors have a more favorable effect on lipid profiles than nonsteroidal aromatase inhibitors in postmenopausal women with early breast cancer: a prospective cohort study.
Journal: Therapeutic advances in medical oncology
Published: January 14, 2020
Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer.
Journal: Breast cancer research and treatment
Published: November 20, 2019
Last Updated: 09/26/2026